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under-shoot the goal AUC (-12.8 % vs. +19.5 %, P ¼ .018), and
require busulfan dose increases (+20% vs. -19.9%, P ¼ .012)
compared to those dosed on actual body weight. A subgroup
analysis conﬁrmed this result for patients receiving Bu/Cy
(-23.6 % vs. +2.2%, P ¼<.001 for goal AUC and +36.2% vs. -4.5
%, P ¼ .008 for busulfan dose changes in adjusted vs. actual
body weight groups, respectively), but not Flu/Bu condi-
tioning regimens (-0.8 % vs. +25.3%, P¼ .123 for goal AUC and
+3.4% vs. -25.1 %, P ¼ .174 for busulfan dose changes in
adjusted vs. actual body weight groups, respectively).
Notably, two patients dosed by actual body weight in the Flu/
Bu group experienced an AUC of > 9000 mmol*min. Time to
neutrophil or platelet engraftment, progression-free survival
and overall survival were not signiﬁcantly different between
those dosed on actual versus adjusted body weight (P > .05).
No neurologic adverse events or VOD incidents were
observed in any group.
Conclusions: Our prospective analysis of IV busulfan
PK data in various myeloablative and non-myeloablative
busulfan based conditioning regimens for HSCT provides
important insight into the choice of appropriate busulfan
dosing weight. Further studies are warranted to elucidate
which weight is most likely to achieve goal area-
under-the curve and subsequent optimal patient
outcomes.541
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Background: Etoposide is an important drug in the
conditioning regimen for hematopoietic stem cell trans-
plant (HSCT). The administration of etoposide in this
patient care setting presents a challenge due to limited
aqueous solubility. As a result of the high doses utilized in
myeloablative regimens, administration is accompanied
by large volumes of intravenous ﬂuids which increase
the risk for volume overload, cardiac dysfunction, and
electrolyte abnormalities. There are published reports
that describe unchanged pharmacokinetic parameters
between diluted and undiluted drug, as well as data
describing the safe use of undiluted drug in the transplant
population.
Methods: We report our experience with eleven patients
who received undiluted etoposide (20 mg/mL) over 4 hours
through a central line in preparation for HSCT. All patients
received an antihistamine and corticosteroid as premed-
ication, as well as another dose of each and acetaminophen
when half of the volume had infused. The etoposide was
infused through DEHP-free tubing into a dedicated lumen.
Vital signs were monitored at baseline, regularly
throughout the infusion, and after the infusion was
complete.
Results: Between April 2 and June 15, 2012, eleven
patients received undiluted etoposide at a dose of 60 mg/
kg. The most common adverse events documented were
gastrointestinal toxicities. All patients reported nausea
and most cases were accompanied by emesis, requiring an
average of 4.4 antiemetic doses for treatment of break-
through nausea/vomiting. Hypotension was documentedin nine patients, with an average drop in systolic blood
pressure of 35 mm Hg (range: 15-46 mm Hg) occurring 6.6
hours (range: 1.7-18.8 hours) after the start of etoposide
infusion. Nine patients required ﬂuid resuscitation with an
average of 1400 mL (range: 500 mL-3500 mL) of normal
saline.
Conclusion: Despite published reports of successful
administration of undiluted etoposide in myeloablative
conditioning regimens, we report numerous adverse events
in our patient population. All patients treated at our insti-
tution with undiluted etoposide as part of the conditioning
regimen experienced side effects related to the drug. The
beneﬁts of administering undiluted etoposide should be
carefully weighed against the possibility of related tox-
icities.542
Delaying the Start of Triazole Prophylaxis 7 Days After
Allogeneic HCT Does Not Affect Outcomes, Including Risk
of Invasive Fungal Infection
Kefei Dai 1, Izaskun Ceberio 2, Sean Devlin 3, Juliet N. Barker 4,
Hugo Castro-Malaspina 4, Jenna Goldberg 4, Sergio A. Giralt 4,
Nelly G. Adel 5, Miguel-Angel Perales 4. 1 Pharmacy, Memorial
Sloan Kettering Cancer Center; 2Memorial Sloan Kettering
Cancer Center; 3 Department of Biostatistics, Memorial Sloan-
Kettering Cancer Center, New York, NY; 4 Department of
Medicine, Adult Bone Marrow Transplant Service, Memorial
Sloan-Kettering Cancer Center, New York, NY; 5Memorial
Sloan-Kettering Cancer Ctr, New York, NY
Introduction: Antifungal prophylaxis with azoles is con-
sidered standard in patients undergoing allo-HCT. However,
azoles have signiﬁcant interactions with immunosuppres-
sive drugs used for graft-versus-host disease (GVHD)
prophylaxis. Since the risk of GVHD is increased in the
setting of sub-therapeutic immunosuppressant levels, we
changed our standard practice from initiating the triazole on
day +3 to day +7 after allo-HCT in order to make the change
at steady state and limit the occurrence of non-therapeutic
levels.
Methods:We retrospectively evaluated 196 patients treated
from Jan 2009 to Nov 2011 to assess the impact of delaying
the start of azole antifungals on immunosuppressive levels,
acute GVHD, and rate of invasive fungal infections (IFI).
Micafungin was given from admission until azole initiation.
Patients received voriconazole (n¼162), posaconazole
(n¼17), ﬂuconazole (n¼9) or were maintained on mica-
fungin (n¼8). Stem cell sources included PBSCT from
related/unrelated donors (n¼139) and cord blood grafts
(n¼57). GVHD prophylaxis was with tacrolimus (tacro) +
sirolimus (siro) + methotrexate (MTX) (n¼76), tacro + MTX
(n¼42), cyclosporine (CSA) + mycophenolate mofetil (MMF)
(n¼57), tacro + MMF (n¼9), tacro + siro (n¼7), CSA + MTX
(n¼3), CSA (n¼1), siro + MMF (n¼1). Results were analyzed
by intent-to-treat (ITT) for patients treated before (day+3
switch, n¼69) or after February 2010 (day+7 switch, n¼127)
as well as by actual day of switch + 1 (day+2,3,4: n¼49 vs.
day+6,7,8: n¼70). Cumulative incidence (CI) functions esti-
mated day 200 grade II-IV aGVHD. Gray's test was used to
compare aGVHD incidence for individuals in the day +3 and
day+7 treatment categories for both the ITT and as-treated
analyses.
Results: Median levels two weeks after HCT were thera-
peutic in 19/19 (100%), 50/52 (96%), 31/32 (97%) patients on
CSA, Tacro, and Siro, respectively, prior to Feb 2010 and in
43/44 (98%), 82/83 (99%), 47/52 (90%), for CSA, Tacro, and
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(95% CI: 0.21, 0.43) and 0.46 (95% CI: 0.37, 0.54) prior to and
after Feb 2010, respectively (P¼ .11). Eighty-six patients
(44%) were considered at high risk for IFI pre-HSCT by
standard criteria. The rate of IFI post HCT was 9/69 (13%)
and 18/127 (14%) prior to and after Feb 2010, respectively.
Proven (n¼2) or probable (n¼2) IFI was only observed in 4
patients (2%), with the remainder having possible IFI.
Subgroup analysis did not ﬁnd any statistical difference
between the two groups for aGVHD analyzed by stem cell
source or IFI analyzed by pre-HSCT risk. In addition, there
was no difference in the number of dose modiﬁcations
required and when patients were analyzed by actual day of
azole start.
Conclusion: Delaying the start of triazole prophylaxis till 7
days after allo-HSCT does not affect outcomes, including
achieving and maintaining therapeutic levels of GVHD
prophylaxis, and incidence of aGVHD or IFI.543
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Cardiac arrhythmias (CA) can be an important complica-
tion of cellular therapy. We performed a retrospective,
single center, comprehensive analysis to understand the
risk factors, outcome and morbidity of cardiac arrhyth-
mias developing in the ﬁrst 100 days after allogeneic
hematopoietic stem cell transplantation in adults. Overall
133 patients received an allogeneic transplant between
01/2008 and 07/2012 and were included in the analysis.
Individuals with pre existing arrhythmias were excluded.
Patients and transplant characteristics are detailed in
Table 1. At least one episode of cardiac arrhythmiaTable 1
Demographics N¼133
Median age (range) 54 (18-70)
Male gender 85 (64%)
Race
African American 25 (19%)
Caucasian 107 (80%)
Other 1 (1%)
Diagnosis
Acute Leukemias 75 (56%)
MDS 20 (15%)
Lymphomas 19 (14%)
CML 11 (8%)
CLL/PLL 5 (4%)
MM 2 (2%)
AA 1 (1%)
Graft source
Adult MUD/MMUD 78 (59%)
Sibling 47 (35%)
Haploidentical family 3 (2%)
Cord blood 5 (4%)
Conditioning
Myeloablative 48 (36%)
RIC/NMA 85 (64%)
Comorbidities
Median left ventricle ejection fraction (range) 60% (33-76)
Hypertension 47 (35%)
Diabetes 26 (20%)
Coronary artery disease 5 (4%)
Smoking history 69 (52%)developed in 25 individuals (18.8%, 95% C.I. 13.0-26.3%)
with 19 individuals developing atrial ﬂutter/ﬁbrillation
and 8 individuals developing AV nodal reentrant tachy-
cardia. Median time of onset of the arrhythmia was 27
days (range 1-96) after transplant. Neither underlying
disease, conditioning regimen, comorbidities, left
ventricular ejection fraction, presence of ventricular dia-
stolic dysfunction, prior use of beta blockers, calcium
channel blockers, ACE inhibitors or ARBs were associated
with higher risk of developing CA in univariate or multi-
variate analysis. Patients who developed CA were older
(median age 56 years) than patients who did not develop
CA (median age 51 years), but this difference was not
statistically signiﬁcant (P ¼ .08). Of the 25 individuals who
developed CA, 13 died prior to day 100 (4 from cardiac
causes). Among the remaining 12 patients, 8 had resto-
ration of sinus rhythm by day 100. Median survival was
14+/- 2 weeks for individuals who developed CA vs. 81 +/-
35 weeks for patients who did not develop CA prior to 100
days (P < .0001). In multivariate analysis, development of
CA prior to 100 days was a strong predictor of mortality
(HR¼2.87, 95% C.I. 1.67-4.95, P ¼ .001) even when adjusted
for age, intensity of the conditioning regimen, comorbid-
ities, chronic medications, left ventricular ejection fraction
and presence of ventricular diastolic dysfunction. We
concluded that the development of CA after allogeneic
transplantation is relatively common, but difﬁcult to
predict on the basis of patient and transplant character-
istics, representing a strong and independent predictor of
post transplant mortality.
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Allogeneic bone marrow transplant (BMT) patients with
cyclosporine-induced hypertension are at risk of serious
complications including intracerebral hemorrhage and
seizures. There is little data describing cyclosporine-
induced hypertension in the allogeneic BMT population.
The aim of this study was to characterize cyclosporine-
induced hypertension in the allogeneic BMT population at
the Medical University of South Carolina (MUSC), while
also investigating what blood pressure (BP) medications
currently used may be most efﬁcacious. We conducted
a single center, IRB approved, retrospective study of
patients receiving an allogeneic BMT from January 1, 2008
to August 31, 2011. Demographic data was collected for all
patients. Those patients experiencing cyclosporine-
induced hypertension had additional data recorded:
number of systolic blood pressure (SBP) readings > 160
mmHG, number of diastolic blood pressure (DBP) readings
>100 mmHg, addition of an antihypertensive medication,
and number of doses and dosage administered. Safety was
assessed through recording number of SBP readings < 100
mmHG, number of DBP readings < 40 mmHg, and the
minimum heart rate (HR) while on cyclosporine. Twenty
seven (27) of 78 patients were identiﬁed as experiencing
